Recent efforts have identified multiple dysregulated signaling pathways in pancreatic cancer development and progression, many of which appear to be reasonable targets including PI3K/mTOR, SIRT1, and ALK [143–146]. This evidence concerns the gene ALK and pancreatic neoplasm.